{"filing":{"accession_number":"0001178913-26-003290","cik":"0001553846","ticker":"RDHL","company_name":"RedHill Biopharma Ltd.","form":"6-K","filing_date":"2026-06-22","report_date":null,"primary_document":"zk2635591.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1553846/000117891326003290/zk2635591.htm"},"events":[{"id":12711,"run_id":11280,"accession_number":"0001178913-26-003290","anchor_item_number":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"RedHill Biopharma entered into a Securities Purchase Agreement on June 18, 2026, for a private placement of 8,571,429 ADSs (each representing 10,000 ordinary shares), Series A-1 and Series A-2 warrants, and pre-funded warrants at a combined purchase price of $0.70 per ADS and accompanying warrants. The offering is expected to generate approximately $6 million in gross proceeds, with potential additional proceeds of $13.4 million if warrants are fully exercised. This is a classic dilutive equity issuance to an accredited investor under Section 4(a)(2) and Regulation D, materially affecting shareholder ownership and voting rights.","company_name":"RedHill Biopharma Ltd.","ticker":"RDHL","filing_date":"2026-06-22","form":"6-K","submitted_at":null,"items":null}],"classifications":[{"id":9640,"accession_number":"0001178913-26-003290","item_number":null,"item_title":null,"event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"RedHill Biopharma entered into a Securities Purchase Agreement on June 18, 2026, for a private placement of 8,571,429 ADSs (each representing 10,000 ordinary shares), Series A-1 and Series A-2 warrants, and pre-funded warrants at a combined purchase price of $0.70 per ADS and accompanying warrants. The offering is expected to generate approximately $6 million in gross proceeds, with potential additional proceeds of $13.4 million if warrants are fully exercised. This is a classic dilutive equity issuance to an accredited investor under Section 4(a)(2) and Regulation D, materially affecting shareholder ownership and voting rights.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-06-22T20:46:26.803516+00:00","company_name":"RedHill Biopharma Ltd.","ticker":"RDHL","filing_date":"2026-06-22"}]}